In vitro metabolism and disposition of honokiol in rat and human livers

Journal of Pharmaceutical Sciences

Volumn 100, Issue 8, 2011, Pages 3506-3516

  Böhmdorfer, Michaela ^a   Maier Salamon, Alexandra ^a   Taferner, Barbara ^a   Reznicek, Gottfried ^a   Thalhammer, Theresia ^b   Hering, Steffen ^a   Hüfner, Antje ^c   Schühly, Wolfgang ^c   Jäger, Walter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

Biliary excretion; Glucuronidation; Hepatic clearance; Hepatic metabolism; Honokiol; Sulfation

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; GLUCURONIC ACID; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A8; HONOKIOL; HONOKIOL MONOGLUCURONIDE; HONOKIOL MONOSULFATE; MAGNOLIA OFFICINALIS EXTRACT; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A2; SULFOTRANSFERASE 1A3; SULFOTRANSFERASE 1B1; SULFOTRANSFERASE 1E1; SULFURIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; BARK; BILE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSFORMATION; ENZYME MECHANISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER CYTOSOL; LIVER PERFUSION; MALE; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; SULFATION;

EID: 79958779622     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22536     Document Type: Article

References (31)

1. Liou KT, Shen YC, Chen CF, Tsao CM, Tsai SK. 2003. The anti-inflammatory effect of honokiol on neutrophils: Mechanisms in the inhibition of reactive oxygen species production. Eur J Pharmacol 475:19-27.
2. Schühly W, Khan SI, Fischer NH. 2009. Neolignans from North American Magnolia species with cyclooxygenase-2 inhibitory activity. Inflammopharmacology 17:106-110.
3. Shen CC, Ni CL, Shen YC, Huang YL, Kuo CH, Wu TS, Chen CC. 2009. Phenolic constituents from the stem bark of Magnolia officinalis. J Nat Prod 72:168-171.
4. Teng CM, Chen CC, Ko FN, Lee LG, Huang TF, Chen YP, Hsu HY. 1988. Two antiplatelet agents from Magnolia officinalis. Thromb Res 50:757-765.
5. Tsai SK, Huang CH, Huang SS, Hung LM, Hong CY. 1999. Antiarrhythmic effect of magnolol and honokiol during acute phase of coronary occlusion in anesthetized rats: Influence of L-NAME and aspirin. Pharmacology 59:227-233.
6. Xu Q, Yi LT, Pan Y, Wang X, Li YC, Li JM, Wang CP, Kong LD. 2008. Antidepressant-like effects of the mixture of honokiol and magnolol from the barks of Magnolia officinalis in stressed rodents. Prog Neuropsychopharmacol Biol Psychiatry 32:715-725.
7. Maruyama Y, Kuribara H, Morita M, Yuzurihara M, Weintraub ST. 1998. Identification of magnolol and honokiol as anxiolytic agents in extracts of saiboku-to, an oriental herbal medicine. J Nat Prod 61:135-138.
8. Kuribara H, Kishi E, Hattori N, Okada M, Maruyama Y. 2000. The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from Magnolia bark. J Pharm Pharmacol 52:1425-1429.
9. Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, Murad E, Dubiel W, Soff G, Arbiser JL. 2003. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 278:35501-35507.
10. Wang T, Chen F, Chen Z, Wu YF, Xu XL, Zheng S, Hu X. 2004. Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. World J Gastroenterol 10:2205-2208.
11. Battle TE, Arbiser J, Frank DA. 2005. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood 106:690-697.
12. Wolf I, O'Kelly J, Wakimoto N, Nguyen A, Amblard F, Karlan BY, Arbiser JL, Koeffler HP. 2007. Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. Int J Oncol 30:1529-1537.
13. Hattori M, Sakamoto T, Endo Y, Kakiuchi N, Kobashi K, Mizuno T, Namba T. 1984. Metabolism of magnolol from magnoliae cortex. I. Application of liquid chromatography-mass spectrometry to the analysis of metabolites of magnolol in rats. Chem Pharm Bull 32:5010-5017.
14. Hattori M, Endo Y, Takebe S, Kobashi K, Fukasaku N, Namba T. 1986. Metabolism of magnolol from Magnoliae cortex. II. Absorption, metabolism and excretion of [ring-14C]magnolol in rats. Chem Pharm Bull 34:158-167.
15. El-Feraly FS, Li WS. 1978. Phenolic constituents of Magnolia grandiflora L. seeds. Lloydia 41:442-449.
16. Thalhammer T, Stapf V, Gajdzik L, Graf J. 1994. Bile canalicular cationic dye secretion as a model for P-glycoprotein mediated transport. Eur J Pharmacol 270:213-220.
17. Soars MG, Ring BJ, Wrighton SA. 2003. The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases. Drug Metab Dispos 31:762-767.
18. Fujita M, Itokawa H, Sashida Y. 1973. Studies on the components of Magnolia obovata Thunb. 3. Occurrence of magnolol and honokiol in M. obovata and other allied plants. Yakugaku Zasshi 93:429-434.
19. Wu X, Chen X, Hu Z. 2003: High-performance liquid chromatographic method for simultaneous determination of honokiol and magnolol in rat plasma. Talanta 59:115-121.
20. Tsai TH, Chou CJ, Cheng FC, Chen CF. 1994. Pharmacokinetics of honokiol after intravenous administration in rats assessed using high-performance liquid chromatography. J Chromatogr Biomed Appl 655:41-45.
21. Tsai TH, Chou CJ, Chen CF. 1996. Pharmacokinetics and brain distribution of magnolol in the rat after intravenous bolus injection. J Pharm Pharmacol 48:57-59.
22. Maier-Salamon A, Hagenauer B, Wirth M, Gabor F, Szekeres T, Jäger W. 2006. Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. Pharm Res 23:2107-2115.
23. Miksits M, Maier-Salamon A, Aust S, Thalhammer T, Reznicek G, Kunert O, Haslinger E, Szekeres T, Jaeger W. 2005. Sulfation of resveratrol in human liver: Evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1. Xenobiotica 35:1101-1119.
24. King CD, Rios GR, Green MD, Tephly TR. 2000. UDP-glucuronosyltransferases. Curr Drug Metab 1:143-161.
25. Nagar S, Remmel RP. 2006. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 25:1659-1672.
26. Glatt, H. 2000. Sulfotransferases in the bioactivation of xenobiotics. Chem Biol Interact 129:141-170.
27. Teubner W, Meinl W, Florian S, Kretzschmar M, Glatt H. 2007. Identification and localization of soluble sulfotransferases in the human gastrointestinal tract. Biochem J 404:207-215.
28. Meinl W, Ebert B, Glatt H, Lampen A. 2008. Sulfotransferase forms expressed in human intestinal Caco-2 and TC7 cells at varying stages of differentiation and role in benzo[a]pyrene metabolism. Drug Metab Dispos 36:276-283.
29. Wang J, Falany JL, Falany CN. 1998. Expression and characterization of a novel thyroid hormone-sulfating form of cytosolic sulfotransferase from human liver. Mol Pharmacol 53:274-282.
30. Otake Y, Nolan AL, Walle UK, Walle T. 2000. Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells. J Steroid Biochem Mol Biol 73:265-270.
31. Pasqualini JR, Chetrite GS. 2005. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 93:221-236.